top of page

Science that improves

quality of life

Scientific innovation and development are the pillars of our company. We're creating technology that transforms each patient's life; technology which will deliver answers today; technology that enhances the clinical management of their condition.

483,000

Number of women with HER2+ Breast Cancer 
in the United States and European Union[4]
Anchor 1
THERANOSTIC SPOTLIGHT

A combined therapeutic and diagnostic approach 

for breast cancer

By integrating imaging and targeted radiotherapy, we are pioneering a personalized approach to the management of each patient's condition using a novel method called theranostics.
AIP is on the frontier of molecular drug development.

95%

of rare diseases have not one single
FDA approved drug treatment[3]
DIAGNOSTIC SPOTLIGHT

First-in-kind diagnostics

exclusively for children struggling with a rare pediatric disease 

We're focused on children and their families first. We understand that each family enduring a rare pediatric disease faces difficulties from diagnosis to treatment. Using novel modalities to diagnose rare
diseases, we're working to ensure that children suffer less.

1.1 million

Oncology and Rare Pediatric Patients whose quality of life will benefit from solutions 
delivered by our pipeline
OUR PIPELINE

Developing tomorrow's breakthroughs

Our experts are accelerating the development pipeline of radiotherapies and PET imaging agents in oncology and rare p pediatric diseases.  
DIAGNOSTIC SPOTLIGHT

A PET imaging agent
for the differential diagnosis
of Breast and Lung Cancer

bottom of page